Experimental drug found to more than double survival time for glioblastoma patients

Published Date: 08 Mar 2025

A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults.

Read Full News

Latest News

Nurses Speak Out on Burnout, Mandatory Overtime, and Burning the Candle at Both Ends

Emotionally drained, sleep-deprived, and skipping meals to keep up: what nurse leaders say needs to change to prevent burnout.

Most Family Physicians Struggle With After-Hours Admin Work

Most family physicians face heavy administrative burden, but improved electronic health records and staff support may help to ease some of the load.

Lawsuit Against Bristol Myers Over Delayed Cancer Drug Is Revived

A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former ⁠Celgene shareholders by delaying...

Residency Reverse: When the Patient's Home Is the Office

Home visits — once common and now resurging — flip the dynamic, as the clinician becomes a guest in the patient's home. Experts say as both learn more about each other than is possible in-office, trust can build.

Federal Agencies Widen Med School Admissions Investigations

Departments of Justice, Education accuse schools of making race-based decisions.

US Senate Panel Advances Trump CDC Pick Schwartz

The U.S. Senate health committee voted on Thursday to advance the nomination of President Donald Trump's pick for CDC director ⁠Dr. Erica Schwartz, handing his...

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Latest News

Emotionally drained, sleep-deprived, and skipping meals to keep up: what nurse leaders say needs to change to prevent burnout.

Most family physicians face heavy administrative burden, but improved electronic health records and staff support may help to ease some of the load.

A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former ⁠Celgene shareholders by delaying...

Home visits — once common and now resurging — flip the dynamic, as the clinician becomes a guest in the patient's home. Experts say as both learn more about each other than is possible in-office, trust can build.

Departments of Justice, Education accuse schools of making race-based decisions.

The U.S. Senate health committee voted on Thursday to advance the nomination of President Donald Trump's pick for CDC director ⁠Dr. Erica Schwartz, handing his...

News All Time

Analysis-Big Pharma Taps UK Playbook to Pressure European Capitals on Drug Prices

Global pharmaceutical companies, facing pushback from European capitals on drug pricing, are turning to a playbook that brought them recent success in Britain: threats of...

Studies Confirm Private Equity Dangers

A handful of studies confirm that hospitals taken over by private equity have worse outcomes for patients.

Cholera Outbreak in Nigeria's Borno Kills 74, Infects Thousands Since May

A cholera outbreak that began in early May in Nigeria's northeastern Borno state ⁠has killed at least 74 people and infected more than 7,800, overwhelming health facilities,...

Nurses Filling Doctor Gaps: What Happens to Hard Cases?

As health systems consider shifting more physician tasks to nurses, Medscape readers focused on whether expanded care models include clear supervision, escalation, and time for patients who do not fit routine protocols.

FDA Grants Emergency Approval for Over-the-counter Drug to Treat Screwworm in Pets

The U.S. Food and Drug Administration on Thursday authorized the emergency use of a generic over-the-counter tablet ⁠to treat infestations caused by the New World screwworm...

More Nurses are Clocking in to Second Jobs

More nurses regularly take on second shifts but as the practice becomes normalized, is this best for patients?

Sandoz Files European Complaint About Chinese Antibiotic Imports

Swiss generic drugmaker Sandoz filed a draft ⁠anti-dumping complaint with the European Commission over Chinese imports ⁠of the antibiotic ingredient amoxicillin.

What Your ZIP Code Is Costing You

Forget salary. The cities winning the physician satisfaction race are playing a completely different game.

How NPs Are Navigating Prior Authorization Coverage Barriers

The same hurdles facing physicians slow treatment for nurse practitioners’ patients, and the impact on care continues.

US FDA Issues Recall Of Boston Scientific Heart Devices

Boston Scientific has issued an urgent recall to correct several heart devices after ⁠the U.S. Food and Drug Administration classified the action as its most serious recall,...

Delays in Visa Program Threaten Hundreds of Doctors

Prolonged HHS J-1 waiver backlogs leave hundreds of foreign-trained doctors facing departure this summer, threatening care in underserved areas, immigration attorneys warn.

AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Europe Risks Falling Behind in Medicine Race, Roche CEO

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

US Health Regulators to Speed Up Medicare Device Coverage

U.S. health regulators announced a new program to speed up Medicare coverage for certain medical devices on ⁠Thursday, saying it would cut reimbursement timelines to as...

Germany Risks Missing Out on New Drugs, AstraZeneca CEO Says

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

U.S. to Ask States to Revalidate "high-risk" Medicaid Providers

Mehmet Oz, who heads the agency that runs the U.S. Medicare and ⁠Medicaid healthcare programs, said on Tuesday the Trump administration plans to ask all ⁠50 states to...

Recommended News For You

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.

Detecting invasive nodules could be key to preventing unnecessary pancreatic cancer surgery

Investigating the Relationship Between GERD and Anxiety/Depression.

A single bout of exercise gives results that could help cancer patients

AI could help improve early detection of interval breast cancers

Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

Recommended Articles For You

Digital Hematology Platforms for Longitudinal Blood Health Analytics 

Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025 

Essential Techniques in Oncology and Quality Improvement 

Emerging Therapies Through Engineered Blood Cell Manufacturing Platforms 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.

2.

Reducing social media to an hour a day boosts young people's self-image.

3.

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

4.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

5.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

1.

General Practitioners Role in Diagnosing Ovarian Cancer

2.

Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion

3.

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency

4.

Everything You Need to Know About RDW-CV: A Comprehensive Guide 

5.

Clinical Trends in Oncology in Clinical Decision-Making

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Understanding Platelet Disorders

2.

Clinical Excellence in Hematology

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

4.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot